COMP <GO>
UHS vs MRK // RSI-14 & 200D SMA MOMENTUM
Universal Health Services Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: UHS 6
— MRK 7
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MRK
LAST: $180.65 (+2.61%) • MKT CAP: $10.38B
rsi-technicals
45.7
LAST: $148.36 (-0.78%) • MKT CAP: $368.89B
rsi-technicals
56.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UHS VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UHS | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | 20.70% | -6.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.0x | 15.3x | -10.30 | UHS | /valuation <GO> |
| Free Cash Flow Yield | 8.16% | 3.42% | +4.74 | UHS | /fcf-yield <GO> |
| Operating Margin | 11.50% | 34.30% | -22.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 8.60% | 28.10% | -19.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 9.70% | 1.30% | +8.40 | UHS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.49% | 2.26% | -1.77 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.11 | 5.19 | -2.08 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | UHS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 45.7 | 56.3 | -10.60 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.92 | +0.12 | UHS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.5x | 18.4x | -11.90 | UHS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.38B | $368.89B | -$358.52B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UHS REV | MRK REV | UHS GROSS % | MRK GROSS % | UHS FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.36B | $65.01B | — | 74.8% | $849.2M | $12.36B |
| FY 2024 | $15.83B | $64.17B | — | 76.3% | $1.12B | $18.10B |
| FY 2023 | $14.28B | $60.12B | — | — | $625.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UHS // BETA 1.04
MRK // BETA 0.92